Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BIOCORNEUM is a leading professional-grade silicone scar treatment brand, widely recognized within the plastic surgery and dermatology communities. The product line utilizes a patented cross-linking silicone gel technology known as Silishield, which creates a protective, breathable, and waterproof environment to optimize the healing of scars. It is distinguished as the first silicone scar gel to incorporate FDA-accepted SPF 30, which helps prevent UV-induced hyperpigmentation in newly formed scar tissue. Originally developed by Enaltus and later owned by Sientra, the brand was acquired by Tiger BioSciences in 2024 following Sientra's restructuring. BIOCORNEUM is clinically proven to flatten, soften, and reduce the redness of scars resulting from surgical procedures, injuries, and burns. The brand remains a gold standard in post-operative scar management for aesthetic and reconstructive surgery.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BIOCORNEUM.